首页> 外文期刊>Asian Journal of Chemistry: An International Quarterly Research Journal of Chemistry >Terpenoids and Its Commercial Utility from Neem: The Nature's Own Pharmacy
【24h】

Terpenoids and Its Commercial Utility from Neem: The Nature's Own Pharmacy

机译:印em中的萜类化合物及其商业用途:大自然自己的药房

获取原文
获取原文并翻译 | 示例
           

摘要

Plant derived bio products have become integral part of world health care system which not only include botanical drugs but also agro chemicals, cosmetics, nutraceuticals, flavors and fragrances and so on. The World Bank estimates that global trade in plant derived products will grow at average 10-12 % per year and will reach whooping USD 123 billion by 2020. Inevitably this brought attention to our sthala vriksha or sacred tree neem (Azadirachta indica) considered as store house of high value products with vast array of biological activities like insecticidal, spermicidal, anticancer, hypoglycemic, antiulcer, antiinflammatory, and many more. However due to inherent complexities in scalability which includes consistent supply chain and difficulty in synthesizing bioactive metabolites using established chemical routes and seasonal variation in bio-efficacy with change in plant chemistry, place, age etc. makes large scale production of most of them is impossible. Hence there is need for a paradigm shift in combining traditional approaches with more sophisticated biotechnological methods to produce these products in heterologous system, thereby enabling a consistent scale-up at a commercial level. This article reviews the terpenoids reported in neem so far, their proposed biosynthetic pathways and potential avenues for expressing them in microbial cell factories.
机译:植物衍生的生物产品已成为世界卫生保健系统不可或缺的一部分,不仅包括植物药,而且还包括农药,化妆品,营养保健品,香料和香精等。世界银行估计,全球植物衍生产品的贸易将以每年平均10-12%的速度增长,到2020年将达到1230亿美元。这不可避免地引起了人们对被视为商店的sthala vriksha或神圣树ne(Azadirachta indica)的关注。具有多种生物活性的高价值产品之家,例如杀虫,杀精子剂,抗癌剂,降糖药,抗溃疡药,抗炎药等。但是,由于可扩展性的内在复杂性,包括一致的供应链和使用已建立的化学路线合成生物活性代谢物的困难,以及随着植物化学,位置,年龄等变化的生物功效的季节性变化,因此无法大规模生产其中大多数。因此,需要将传统方法与更复杂的生物技术方法相结合以在异源系统中生产这些产品的范式转变,从而实现在商业水平上的一致放大。本文回顾了迄今为止在印em中报道的萜类化合物,其拟议的生物合成途径以及在微生物细胞工厂中表达它们的潜在途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号